Windy City Wound Care maintains a deliberately curated allograft and biologic matrix portfolio, selected to support complex wound healing while remaining aligned with evolving reimbursement frameworks, documentation requirements, and clinical appropriateness standards.
Product selection is based on wound etiology, depth, tissue quality, exudate burden, perfusion status, infection control, and response to prior standard therapies. Advanced biologics are considered only after appropriate conservative measures have been optimized and documented.
Grafix PL
Grafix PL is a cryopreserved placental membrane that preserves native extracellular matrix, endogenous growth factors, and viable cells. Unlike dehydrated products, cryopreservation allows retention of the biologic architecture necessary to support cellular signaling and angiogenesis.
Clinically, Grafix PL is utilized in stalled or complex wounds where impaired cellular migration, ischemia, or chronic inflammation has limited progress under standard care. It supports re-epithelialization by providing a biologically active scaffold that promotes fibroblast migration, endothelial cell activity, and neovascularization.
Common indications include chronic diabetic foot ulcers, venous leg ulcers, and select pressure injuries that have failed to demonstrate measurable improvement despite appropriate offloading, compression, and local wound care.
OASIS® Wound Matrix
OASIS is a porcine-derived acellular collagen matrix designed to provide a structural scaffold for granulation tissue formation. Its extracellular matrix composition supports cellular infiltration while gradually resorbing as native tissue develops.
This product is typically utilized in superficial to moderately deep wounds where the primary goal is to accelerate granulation and epithelial migration after the wound bed has been adequately prepared. OASIS is well suited for wounds with clean, viable tissue and manageable exudate levels.
It is frequently incorporated into treatment plans for venous ulcers, traumatic wounds, and post-debridement surgical wounds when biologic support is indicated but prolonged matrix persistence is not required.
OASIS® Ultra
OASIS Ultra is a thicker, reinforced version of the standard OASIS matrix, engineered to provide extended durability and resistance to degradation in more challenging wound environments.
This product is selected for deeper wounds, wounds with higher exudate burden, or areas exposed to increased mechanical stress, where a longer-lasting collagen scaffold is beneficial. Its increased thickness allows for improved structural support while maintaining biocompatibility and gradual resorption.
OASIS Ultra is commonly used when standard collagen matrices fail to persist long enough to support adequate granulation, particularly in wounds with depth, undermining, or recurrent tissue breakdown.
NovaShield
NovaShield is a protective wound matrix designed to stabilize the wound bed while supporting the body’s intrinsic regenerative processes. It functions as a temporary biologic barrier, helping maintain a controlled wound environment during critical phases of healing.
Clinically, NovaShield is used when wound bed protection and stabilization are priorities—such as after sharp debridement, in fragile granulation tissue, or when shear forces and mechanical disruption pose a risk to healing.
Its role is often adjunctive, supporting tissue regeneration while reducing local trauma and maintaining moisture balance.
Axolotl
Axolotl is a placental-derived allograft developed to address the dysregulated inflammatory environment characteristic of chronic non-healing wounds. It contains bioactive components that help modulate inflammation while supporting tissue repair mechanisms.
This product is typically considered for wounds that demonstrate persistent inflammation, repeated breakdown, or minimal response to prior advanced therapies. By influencing cytokine activity and cellular signaling, Axolotl supports transition from a chronic inflammatory state toward active healing.
It is frequently incorporated into care plans for long-standing diabetic ulcers, pressure injuries, and wounds complicated by systemic inflammatory burden.
Amnio-Maxx
Amnio-Maxx is a dehydrated amniotic membrane allograft rich in growth factors, cytokines, and anti-inflammatory mediators. It supports epithelialization while helping regulate excessive inflammation at the wound surface.
Its dehydrated format allows for ease of storage and handling while still providing biologic activity. Amnio-Maxx is often utilized in superficial to moderately deep wounds where epithelial advancement is the primary clinical objective.
This product is commonly selected when reducing inflammation, supporting keratinocyte migration, and accelerating surface closure are key treatment goals.
Derm-Maxx
Derm-Maxx is an acellular dermal matrix designed to provide structural integrity in wounds with significant dermal tissue loss. It supports tissue ingrowth by acting as a framework for fibroblast infiltration and neovascularization.
This matrix is particularly useful in deep or complex wounds where dermal architecture has been compromised and standard collagen products do not provide sufficient support. Derm-Maxx is often incorporated into staged treatment plans requiring prolonged structural reinforcement.
Its role is typically restorative, addressing deficits in the wound’s foundational tissue layers.
Abio XPL
Abio XPL is a collagen-based extracellular matrix engineered to support granulation tissue development and wound closure across a broad range of wound etiologies.
It provides a biocompatible scaffold that facilitates cellular migration and capillary formation while integrating into the wound bed over time. Abio XPL is commonly used in wounds transitioning from inflammatory to proliferative phases, particularly after effective debridement and infection control.
Its versatility makes it suitable for both chronic and acute wounds requiring biologic support beyond standard dressings.
HeliColl
HeliColl is a collagen wound matrix designed to promote cellular infiltration and granulation tissue formation in appropriately prepared wound beds.
It is typically used in clean, well-vascularized wounds where collagen support can accelerate healing progression. HeliColl assists in moisture balance while providing a structural framework for tissue regeneration.
This matrix is frequently utilized as part of step-wise wound management strategies when moving beyond traditional dressings but before escalation to more complex biologic constructs.
| Product | Source / Type | Thickness & Persistence | Primary Clinical Role | Typical Wound Characteristics | Common Use Positioning |
|---|---|---|---|---|---|
| Grafix PL | Cryopreserved placental membrane | Thin, biologically active; viable cells retained | Promote angiogenesis and cellular migration | Stalled, chronic wounds with impaired healing response | Escalation after failure of optimized standard care |
| OASIS | Porcine-derived collagen matrix | Thin; moderate persistence | Scaffold for granulation and epithelialization | Superficial–moderate depth, clean wound beds | Early biologic support when granulation is limited |
| OASIS Ultra | Reinforced porcine collagen matrix | Thicker; extended durability | Structural support in higher-stress environments | Deeper wounds, higher exudate, mechanical stress | When standard collagen resorbs too quickly |
| NovaShield | Protective wound matrix | Variable; barrier-focused | Wound bed stabilization and protection | Fragile granulation, post-debridement beds | Adjunct for protection and tissue preservation |
| Axolotl | Placental-derived allograft | Moderate persistence | Modulation of chronic inflammation | Long-standing non-healing wounds | Chronic wounds with inflammatory dominance |
| Amnio-Maxx | Dehydrated amniotic membrane | Thin; shorter persistence | Support epithelial migration and inflammation control | Superficial–moderate wounds nearing closure | Surface-driven healing phase |
| Derm-Maxx | Acellular dermal matrix | Thick; long-lasting | Structural replacement of dermal deficits | Deep wounds with tissue loss | Restorative framework in complex wounds |
| Abio XPL | Collagen-based ECM | Moderate persistence | Support granulation and wound closure | Broad etiologies, post-debridement | Transitional biologic support |
| HeliColl | Collagen wound matrix | Thin–moderate | Cellular infiltration and granulation | Clean, well-vascularized wound beds | Step-up from standard dressings |
Product Selection Is Wound-Driven, Not Product-Driven
Advanced biologics and matrices are selected based on wound characteristics and response to prior therapy, not product availability. Factors guiding selection include wound depth, tissue quality, inflammatory status, exudate burden, mechanical stress, perfusion, and documented failure of standard care.
This approach ensures alignment with clinical best practices and payer expectations.
Stepwise Escalation Framework
Windy City Wound Care follows a stepwise escalation model:
Standard wound care optimization → Appropriate debridement and offloading → Infection and ischemia management → Targeted biologic or matrix selection
Advanced products are introduced only when objective measures demonstrate inadequate healing progression despite appropriate conservative management.
Documentation & Utilization Considerations
Each biologic application is supported by:
- Clear documentation of wound chronicity and prior treatments
- Objective measurements demonstrating stalled healing
- Product selection rationale tied to wound depth, tissue deficit, or inflammatory burden
- Ongoing reassessment to confirm continued clinical benefit
Products are discontinued or transitioned when healing trajectory improves or when clinical response is no longer evident.
Portfolio Curation Philosophy
Maintaining a limited, intentional portfolio allows clinicians to match products precisely to wound needs while avoiding unnecessary variation. This supports consistency in outcomes, documentation clarity, and responsible utilization across diverse care settings.